JP2012512906A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512906A5 JP2012512906A5 JP2011542506A JP2011542506A JP2012512906A5 JP 2012512906 A5 JP2012512906 A5 JP 2012512906A5 JP 2011542506 A JP2011542506 A JP 2011542506A JP 2011542506 A JP2011542506 A JP 2011542506A JP 2012512906 A5 JP2012512906 A5 JP 2012512906A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aliphatic
- optionally substituted
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 406
- 125000001931 aliphatic group Chemical group 0.000 claims description 404
- 150000001875 compounds Chemical class 0.000 claims description 361
- 229910052799 carbon Inorganic materials 0.000 claims description 181
- 229910052717 sulfur Inorganic materials 0.000 claims description 157
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 155
- 125000005843 halogen group Chemical group 0.000 claims description 151
- 229910052739 hydrogen Inorganic materials 0.000 claims description 147
- 229910052760 oxygen Inorganic materials 0.000 claims description 141
- 125000005842 heteroatom Chemical group 0.000 claims description 121
- 229910052757 nitrogen Inorganic materials 0.000 claims description 113
- 125000000623 heterocyclic group Chemical group 0.000 claims description 106
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 104
- 239000001301 oxygen Chemical group 0.000 claims description 104
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 103
- 239000011593 sulfur Chemical group 0.000 claims description 103
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 82
- 125000004429 atom Chemical group 0.000 claims description 64
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 63
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 61
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 59
- 125000003386 piperidinyl group Chemical group 0.000 claims description 57
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 54
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 53
- 125000003118 aryl group Chemical group 0.000 claims description 52
- 125000004193 piperazinyl group Chemical group 0.000 claims description 51
- 125000005960 1,4-diazepanyl group Chemical group 0.000 claims description 48
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 229910052736 halogen Inorganic materials 0.000 claims description 38
- 150000002367 halogens Chemical class 0.000 claims description 38
- 125000003725 azepanyl group Chemical group 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 34
- 125000004076 pyridyl group Chemical group 0.000 claims description 34
- 125000002950 monocyclic group Chemical group 0.000 claims description 32
- -1 2 - piperidinyl Chemical group 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 24
- 125000001153 fluoro group Chemical group F* 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 229920006395 saturated elastomer Polymers 0.000 claims description 24
- 125000002619 bicyclic group Chemical group 0.000 claims description 23
- 239000003112 inhibitor Substances 0.000 claims description 23
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 208000009956 adenocarcinoma Diseases 0.000 claims description 18
- 125000004122 cyclic group Chemical group 0.000 claims description 16
- 201000009030 Carcinoma Diseases 0.000 claims description 14
- 125000001544 thienyl group Chemical group 0.000 claims description 14
- 229910052697 platinum Inorganic materials 0.000 claims description 13
- 206010025323 Lymphomas Diseases 0.000 claims description 12
- 206010039491 Sarcoma Diseases 0.000 claims description 12
- 125000002971 oxazolyl group Chemical group 0.000 claims description 12
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 11
- 230000000340 anti-metabolite Effects 0.000 claims description 11
- 229940100197 antimetabolite Drugs 0.000 claims description 11
- 239000002256 antimetabolite Substances 0.000 claims description 11
- 125000002393 azetidinyl group Chemical group 0.000 claims description 11
- 206010016629 fibroma Diseases 0.000 claims description 10
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 10
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 125000002757 morpholinyl group Chemical group 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 206010024612 Lipoma Diseases 0.000 claims description 8
- 229940100198 alkylating agent Drugs 0.000 claims description 8
- 239000002168 alkylating agent Substances 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 8
- 230000005865 ionizing radiation Effects 0.000 claims description 8
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 229960005079 pemetrexed Drugs 0.000 claims description 7
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 7
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 6
- 102100039116 DNA repair protein RAD50 Human genes 0.000 claims description 6
- 102100033996 Double-strand break repair protein MRE11 Human genes 0.000 claims description 6
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 6
- 206010018338 Glioma Diseases 0.000 claims description 6
- 102100034533 Histone H2AX Human genes 0.000 claims description 6
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 6
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 claims description 6
- 101000591400 Homo sapiens Double-strand break repair protein MRE11 Proteins 0.000 claims description 6
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 claims description 6
- 101000581326 Homo sapiens Mediator of DNA damage checkpoint protein 1 Proteins 0.000 claims description 6
- 101001128138 Homo sapiens NACHT, LRR and PYD domains-containing protein 2 Proteins 0.000 claims description 6
- 101000981336 Homo sapiens Nibrin Proteins 0.000 claims description 6
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims description 6
- 102100027643 Mediator of DNA damage checkpoint protein 1 Human genes 0.000 claims description 6
- 102100024403 Nibrin Human genes 0.000 claims description 6
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims description 6
- 206010043276 Teratoma Diseases 0.000 claims description 6
- 102000000504 Tumor Suppressor p53-Binding Protein 1 Human genes 0.000 claims description 6
- 108010041385 Tumor Suppressor p53-Binding Protein 1 Proteins 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 201000011066 hemangioma Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 230000028617 response to DNA damage stimulus Effects 0.000 claims description 6
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 5
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 5
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 5
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 5
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims description 5
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 5
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 5
- 229940127093 camptothecin Drugs 0.000 claims description 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 5
- 229960004562 carboplatin Drugs 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 229960002436 cladribine Drugs 0.000 claims description 5
- 229960000684 cytarabine Drugs 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 5
- 229960005420 etoposide Drugs 0.000 claims description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical group COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 5
- 229960000390 fludarabine Drugs 0.000 claims description 5
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 5
- 229960002949 fluorouracil Drugs 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 229960005277 gemcitabine Drugs 0.000 claims description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 229960004768 irinotecan Drugs 0.000 claims description 5
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 5
- 229960001428 mercaptopurine Drugs 0.000 claims description 5
- 229960000485 methotrexate Drugs 0.000 claims description 5
- 229950007221 nedaplatin Drugs 0.000 claims description 5
- 229960001756 oxaliplatin Drugs 0.000 claims description 5
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 claims description 5
- 229950009213 rubitecan Drugs 0.000 claims description 5
- 229960005399 satraplatin Drugs 0.000 claims description 5
- 190014017285 satraplatin Chemical compound 0.000 claims description 5
- 229960000303 topotecan Drugs 0.000 claims description 5
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 5
- 201000003076 Angiosarcoma Diseases 0.000 claims description 4
- 206010007275 Carcinoid tumour Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 208000002927 Hamartoma Diseases 0.000 claims description 4
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 4
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 4
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 claims description 4
- 201000004404 Neurofibroma Diseases 0.000 claims description 4
- 208000000035 Osteochondroma Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 208000002458 carcinoid tumor Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000001605 fetal effect Effects 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 201000010260 leiomyoma Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 206010027191 meningioma Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 210000000214 mouth Anatomy 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 102000002554 Cyclin A Human genes 0.000 claims description 3
- 108010068192 Cyclin A Proteins 0.000 claims description 3
- 102000003909 Cyclin E Human genes 0.000 claims description 3
- 108090000257 Cyclin E Proteins 0.000 claims description 3
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims description 3
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims description 3
- 230000005778 DNA damage Effects 0.000 claims description 3
- 231100000277 DNA damage Toxicity 0.000 claims description 3
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 claims description 3
- 101710113436 GTPase KRas Proteins 0.000 claims description 3
- 102100039788 GTPase NRas Human genes 0.000 claims description 3
- 101001060231 Homo sapiens F-box/WD repeat-containing protein 7 Proteins 0.000 claims description 3
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 108700020796 Oncogene Proteins 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 150000008052 alkyl sulfonates Chemical class 0.000 claims description 3
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 claims description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 3
- 229960004961 mechlorethamine Drugs 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 3
- 229960000624 procarbazine Drugs 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 239000002534 radiation-sensitizing agent Substances 0.000 claims description 3
- 230000008439 repair process Effects 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 238000009097 single-agent therapy Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229960003087 tioguanine Drugs 0.000 claims description 3
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims description 3
- AYNNSCRYTDRFCP-UHFFFAOYSA-N triazene Chemical compound NN=N AYNNSCRYTDRFCP-UHFFFAOYSA-N 0.000 claims description 3
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 2
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical group C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 241000321096 Adenoides Species 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 claims description 2
- 206010006417 Bronchial carcinoma Diseases 0.000 claims description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- 208000009458 Carcinoma in Situ Diseases 0.000 claims description 2
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 claims description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
- 206010008263 Cervical dysplasia Diseases 0.000 claims description 2
- 201000005262 Chondroma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 201000009047 Chordoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 206010048832 Colon adenoma Diseases 0.000 claims description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 claims description 2
- 206010062805 Dysplastic naevus Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 201000006850 Familial medullary thyroid carcinoma Diseases 0.000 claims description 2
- 208000007659 Fibroadenoma Diseases 0.000 claims description 2
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims description 2
- 208000000527 Germinoma Diseases 0.000 claims description 2
- 208000007569 Giant Cell Tumors Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 206010018404 Glucagonoma Diseases 0.000 claims description 2
- 206010018691 Granuloma Diseases 0.000 claims description 2
- 206010019629 Hepatic adenoma Diseases 0.000 claims description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 2
- 208000002260 Keloid Diseases 0.000 claims description 2
- 206010023330 Keloid scar Diseases 0.000 claims description 2
- 206010023347 Keratoacanthoma Diseases 0.000 claims description 2
- 208000002404 Liver Cell Adenoma Diseases 0.000 claims description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 2
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 2
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 2
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 claims description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 206010048215 Xanthomatosis Diseases 0.000 claims description 2
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 claims description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims description 2
- 229960004176 aclarubicin Drugs 0.000 claims description 2
- 229930183665 actinomycin Natural products 0.000 claims description 2
- 210000002534 adenoid Anatomy 0.000 claims description 2
- 210000004100 adrenal gland Anatomy 0.000 claims description 2
- 229960000473 altretamine Drugs 0.000 claims description 2
- 229960003896 aminopterin Drugs 0.000 claims description 2
- 229960002550 amrubicin Drugs 0.000 claims description 2
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims description 2
- 229960002756 azacitidine Drugs 0.000 claims description 2
- LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 claims description 2
- 229950011276 belotecan Drugs 0.000 claims description 2
- 229960002707 bendamustine Drugs 0.000 claims description 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 2
- 210000003445 biliary tract Anatomy 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 201000003149 breast fibroadenoma Diseases 0.000 claims description 2
- 210000003123 bronchiole Anatomy 0.000 claims description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 2
- 201000002143 bronchus adenoma Diseases 0.000 claims description 2
- 229960002092 busulfan Drugs 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 229960003261 carmofur Drugs 0.000 claims description 2
- 229960005243 carmustine Drugs 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 208000019065 cervical carcinoma Diseases 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 201000005217 chondroblastoma Diseases 0.000 claims description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims description 2
- 229960000928 clofarabine Drugs 0.000 claims description 2
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 210000002615 epidermis Anatomy 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 229960001842 estramustine Drugs 0.000 claims description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229960000961 floxuridine Drugs 0.000 claims description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 2
- 201000000052 gastrinoma Diseases 0.000 claims description 2
- 201000003115 germ cell cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000006359 hepatoblastoma Diseases 0.000 claims description 2
- 201000002735 hepatocellular adenoma Diseases 0.000 claims description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000908 idarubicin Drugs 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 201000004933 in situ carcinoma Diseases 0.000 claims description 2
- 206010022498 insulinoma Diseases 0.000 claims description 2
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims description 2
- 210000001117 keloid Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000022013 kidney Wilms tumor Diseases 0.000 claims description 2
- 210000002429 large intestine Anatomy 0.000 claims description 2
- 210000000867 larynx Anatomy 0.000 claims description 2
- 210000000088 lip Anatomy 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 229950008991 lobaplatin Drugs 0.000 claims description 2
- 229960002247 lomustine Drugs 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000004593 malignant giant cell tumor Diseases 0.000 claims description 2
- 201000000289 malignant teratoma Diseases 0.000 claims description 2
- UUVIQYKKKBJYJT-ZYUZMQFOSA-N mannosulfan Chemical compound CS(=O)(=O)OC[C@@H](OS(C)(=O)=O)[C@@H](O)[C@H](O)[C@H](OS(C)(=O)=O)COS(C)(=O)=O UUVIQYKKKBJYJT-ZYUZMQFOSA-N 0.000 claims description 2
- 229960000733 mannosulfan Drugs 0.000 claims description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 210000002418 meninge Anatomy 0.000 claims description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 claims description 2
- 208000009091 myxoma Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 208000004649 neutrophil actin dysfunction Diseases 0.000 claims description 2
- 229960001420 nimustine Drugs 0.000 claims description 2
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims description 2
- 210000005179 oral vestibule Anatomy 0.000 claims description 2
- 208000003388 osteoid osteoma Diseases 0.000 claims description 2
- 208000008798 osteoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000003101 oviduct Anatomy 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 2
- 208000007312 paraganglioma Diseases 0.000 claims description 2
- 229960002340 pentostatin Drugs 0.000 claims description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 208000028591 pheochromocytoma Diseases 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 229950005566 picoplatin Drugs 0.000 claims description 2
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims description 2
- 229960001221 pirarubicin Drugs 0.000 claims description 2
- 229960003171 plicamycin Drugs 0.000 claims description 2
- 229960004694 prednimustine Drugs 0.000 claims description 2
- 230000001855 preneoplastic effect Effects 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 229960002185 ranimustine Drugs 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 201000006845 reticulosarcoma Diseases 0.000 claims description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 2
- 229960003440 semustine Drugs 0.000 claims description 2
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000003625 skull Anatomy 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 229960001052 streptozocin Drugs 0.000 claims description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 2
- 210000002536 stromal cell Anatomy 0.000 claims description 2
- 229960001674 tegafur Drugs 0.000 claims description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims description 2
- 229960004964 temozolomide Drugs 0.000 claims description 2
- 229960001278 teniposide Drugs 0.000 claims description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
- 208000001608 teratocarcinoma Diseases 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 2
- 229960001196 thiotepa Drugs 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims description 2
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 claims description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
- 210000002105 tongue Anatomy 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 229960003181 treosulfan Drugs 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 229950002860 triplatin tetranitrate Drugs 0.000 claims description 2
- 190014017283 triplatin tetranitrate Chemical compound 0.000 claims description 2
- 229960000875 trofosfamide Drugs 0.000 claims description 2
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 claims description 2
- 208000022271 tubular adenoma Diseases 0.000 claims description 2
- 229960001055 uracil mustard Drugs 0.000 claims description 2
- 210000003708 urethra Anatomy 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 229960000653 valrubicin Drugs 0.000 claims description 2
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims description 2
- 208000009540 villous adenoma Diseases 0.000 claims description 2
- 210000003905 vulva Anatomy 0.000 claims description 2
- 229960000641 zorubicin Drugs 0.000 claims description 2
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 102000000872 ATM Human genes 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 239000012623 DNA damaging agent Substances 0.000 claims 2
- 208000005890 Neuroma Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 125000005959 diazepanyl group Chemical group 0.000 claims 1
- 210000002816 gill Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 76
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 11
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 8
- 102000002804 Ataxia Telangiectasia Mutated Proteins Human genes 0.000 description 6
- 0 CCNC1(*)CCCCCCCCC1 Chemical compound CCNC1(*)CCCCCCCCC1 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 4
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 4
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 4
- 150000003852 triazoles Chemical class 0.000 description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229960005235 piperonyl butoxide Drugs 0.000 description 2
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- KKLNOUVYLCYQTR-UHFFFAOYSA-N CC(C)/S(/c(cc1)ccc1-c(nc1-c2nnc(-c3ccc(C(CF)N)cc3)[o]2)cnc1N)=C/C Chemical compound CC(C)/S(/c(cc1)ccc1-c(nc1-c2nnc(-c3ccc(C(CF)N)cc3)[o]2)cnc1N)=C/C KKLNOUVYLCYQTR-UHFFFAOYSA-N 0.000 description 1
- QABIPNBZTMMIKV-UHFFFAOYSA-N CC(C)S(c(cc1)ccc1-c(nc1-c2cc(-c(cc3)ccc3N(C)CCOCCO)n[o]2)cnc1N)(=O)=O Chemical compound CC(C)S(c(cc1)ccc1-c(nc1-c2cc(-c(cc3)ccc3N(C)CCOCCO)n[o]2)cnc1N)(=O)=O QABIPNBZTMMIKV-UHFFFAOYSA-N 0.000 description 1
- MRJMZPJFDBMWEP-UHFFFAOYSA-N CC(CNCc(cc1)ccc1-c1n[o]c(-c2nc(-c(cc3)ccc3S(C(C)CCO)(=O)=O)cnc2N)c1)F Chemical compound CC(CNCc(cc1)ccc1-c1n[o]c(-c2nc(-c(cc3)ccc3S(C(C)CCO)(=O)=O)cnc2N)c1)F MRJMZPJFDBMWEP-UHFFFAOYSA-N 0.000 description 1
- JJBPRLCLTDGTKJ-UHFFFAOYSA-N CCC(C)S(c(cc1)ccc1-c(nc1-c2cc(-c3ccc(C(CF)N)cc3)n[o]2)cnc1N)(=O)=O Chemical compound CCC(C)S(c(cc1)ccc1-c(nc1-c2cc(-c3ccc(C(CF)N)cc3)n[o]2)cnc1N)(=O)=O JJBPRLCLTDGTKJ-UHFFFAOYSA-N 0.000 description 1
- IMRNBHYTRHNRSJ-UHFFFAOYSA-N CCC(C)S1(C=C1)c(cc1)ccc1-c(nc1-c2cc(-c3ccc(C(C(F)F)N)cc3)n[o]2)cnc1N Chemical compound CCC(C)S1(C=C1)c(cc1)ccc1-c(nc1-c2cc(-c3ccc(C(C(F)F)N)cc3)n[o]2)cnc1N IMRNBHYTRHNRSJ-UHFFFAOYSA-N 0.000 description 1
- JIZVRYYRZNGWLD-UHFFFAOYSA-N NC(CF)c1ccc(-c2n[o]c(-c3nc(-c(cc4)ccc4S(C4COCC4)(=O)=O)cnc3N)c2)c(F)c1 Chemical compound NC(CF)c1ccc(-c2n[o]c(-c3nc(-c(cc4)ccc4S(C4COCC4)(=O)=O)cnc3N)c2)c(F)c1 JIZVRYYRZNGWLD-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- JMVPFKZRJBWAEK-UHFFFAOYSA-N n,n-dimethyloxan-2-amine Chemical group CN(C)C1CCCCO1 JMVPFKZRJBWAEK-UHFFFAOYSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003527 tetrahydropyrans Chemical group 0.000 description 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13942608P | 2008-12-19 | 2008-12-19 | |
| US13942008P | 2008-12-19 | 2008-12-19 | |
| US13942908P | 2008-12-19 | 2008-12-19 | |
| US13942408P | 2008-12-19 | 2008-12-19 | |
| US61/139,424 | 2008-12-19 | ||
| US61/139,420 | 2008-12-19 | ||
| US61/139,429 | 2008-12-19 | ||
| US61/139,426 | 2008-12-19 | ||
| US18179409P | 2009-05-28 | 2009-05-28 | |
| US61/181,794 | 2009-05-28 | ||
| US21910009P | 2009-06-22 | 2009-06-22 | |
| US61/219,100 | 2009-06-22 | ||
| PCT/US2009/068827 WO2010071837A1 (en) | 2008-12-19 | 2009-12-18 | Pyrazine derivatives useful as inhibitors of atr kinase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014171200A Division JP5894643B2 (ja) | 2008-12-19 | 2014-08-26 | Ａｔｒキナーゼのインヒビターとして有用なピラジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012512906A JP2012512906A (ja) | 2012-06-07 |
| JP2012512906A5 true JP2012512906A5 (enExample) | 2013-02-14 |
| JP5753093B2 JP5753093B2 (ja) | 2015-07-22 |
Family
ID=41683104
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542506A Active JP5753093B2 (ja) | 2008-12-19 | 2009-12-18 | Ａｔｒキナーゼのインヒビターとして有用なピラジン誘導体 |
| JP2014171200A Expired - Fee Related JP5894643B2 (ja) | 2008-12-19 | 2014-08-26 | Ａｔｒキナーゼのインヒビターとして有用なピラジン誘導体 |
| JP2015198400A Active JP6212527B2 (ja) | 2008-12-19 | 2015-10-06 | Ａｔｒキナーゼのインヒビターとして有用なピラジン誘導体 |
| JP2017157105A Active JP6577537B2 (ja) | 2008-12-19 | 2017-08-16 | Ａｔｒキナーゼのインヒビターとして有用なピラジン誘導体 |
| JP2019130031A Withdrawn JP2019194250A (ja) | 2008-12-19 | 2019-07-12 | Ａｔｒキナーゼのインヒビターとして有用なピラジン誘導体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014171200A Expired - Fee Related JP5894643B2 (ja) | 2008-12-19 | 2014-08-26 | Ａｔｒキナーゼのインヒビターとして有用なピラジン誘導体 |
| JP2015198400A Active JP6212527B2 (ja) | 2008-12-19 | 2015-10-06 | Ａｔｒキナーゼのインヒビターとして有用なピラジン誘導体 |
| JP2017157105A Active JP6577537B2 (ja) | 2008-12-19 | 2017-08-16 | Ａｔｒキナーゼのインヒビターとして有用なピラジン誘導体 |
| JP2019130031A Withdrawn JP2019194250A (ja) | 2008-12-19 | 2019-07-12 | Ａｔｒキナーゼのインヒビターとして有用なピラジン誘導体 |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US8841308B2 (enExample) |
| EP (3) | EP3354650B1 (enExample) |
| JP (5) | JP5753093B2 (enExample) |
| KR (3) | KR101958632B1 (enExample) |
| CN (4) | CN106496210B (enExample) |
| AR (1) | AR074822A1 (enExample) |
| AU (3) | AU2009327357C1 (enExample) |
| BR (1) | BRPI0924084B1 (enExample) |
| CA (2) | CA2747252C (enExample) |
| CY (1) | CY1120002T1 (enExample) |
| DK (2) | DK3354650T3 (enExample) |
| ES (2) | ES2921576T3 (enExample) |
| HR (2) | HRP20180385T1 (enExample) |
| HU (1) | HUE036068T2 (enExample) |
| IL (3) | IL213613A (enExample) |
| LT (2) | LT2376485T (enExample) |
| MX (1) | MX2011006503A (enExample) |
| NO (1) | NO2376485T3 (enExample) |
| NZ (1) | NZ593969A (enExample) |
| PL (2) | PL3354650T3 (enExample) |
| PT (2) | PT2376485T (enExample) |
| RS (1) | RS56995B1 (enExample) |
| RU (2) | RU2604066C2 (enExample) |
| SG (2) | SG10201607592PA (enExample) |
| SI (2) | SI2376485T1 (enExample) |
| SM (1) | SMT201800181T1 (enExample) |
| TW (3) | TWI543979B (enExample) |
| WO (1) | WO2010071837A1 (enExample) |
| ZA (1) | ZA201104498B (enExample) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5702293B2 (ja) | 2008-11-10 | 2015-04-15 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| BRPI0924084B1 (pt) | 2008-12-19 | 2021-12-21 | Vertex Pharmaceuticals Incorporated | Derivados de pirazina e composição farmacêutica que os compreende |
| US8415381B2 (en) * | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| AU2011253025A1 (en) * | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| EP2569287B1 (en) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2011143422A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
| JP2013526538A (ja) * | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2011163527A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| US8962623B2 (en) | 2011-03-04 | 2015-02-24 | Locus Pharmaceuticals, Inc. | Aminopyrazine compounds |
| KR20130133051A (ko) | 2011-03-16 | 2013-12-05 | 에프. 호프만-라 로슈 아게 | 6,5-헤테로사이클릭 프로파길릭 알콜 화합물 및 이의 용도 |
| WO2012138938A1 (en) * | 2011-04-05 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
| CA2832605C (en) * | 2011-05-23 | 2016-03-29 | Merck Patent Gmbh | Pyridine-and pyrazine derivatives |
| EP2723745A1 (en) * | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
| IN2014CN02501A (enExample) * | 2011-09-30 | 2015-06-26 | Vertex Pharma | |
| WO2013049719A1 (en) * | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013049720A1 (en) * | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| SG10201606774UA (en) * | 2011-09-30 | 2016-10-28 | Vertex Pharma | Processes for making compounds useful as inhibitors of atr kinase |
| MX2014003796A (es) * | 2011-09-30 | 2015-01-16 | Vertex Pharma | Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
| EP2776429A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776422A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776421A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013071093A1 (en) * | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US20140044802A1 (en) * | 2012-04-05 | 2014-02-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| SI3459942T1 (sl) | 2012-04-24 | 2021-05-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| SMT202000713T1 (it) * | 2012-12-07 | 2021-03-15 | Vertex Pharma | Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro |
| WO2014106612A1 (en) * | 2013-01-02 | 2014-07-10 | H. Lundbeck A/S | Aminopyridine derived compounds as lrrk2 inhibitors |
| RU2644769C2 (ru) | 2013-01-23 | 2018-02-14 | Астразенека Аб | Химические соединения |
| HUE041544T2 (hu) | 2013-03-12 | 2019-05-28 | Vertex Pharma | DNS-PK inhibitorok |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| PT3424920T (pt) | 2013-10-17 | 2020-07-07 | Vertex Pharma | Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk |
| HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| CN103804312B (zh) * | 2014-02-17 | 2016-04-20 | 四川百利药业有限责任公司 | 一类氮杂环化合物及其制备方法和用途 |
| EP3134397A1 (en) * | 2014-04-24 | 2017-03-01 | Novartis AG | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| PL3134395T3 (pl) | 2014-04-24 | 2018-07-31 | Novartis Ag | Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu |
| US10112926B2 (en) | 2014-04-24 | 2018-10-30 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
| AU2015252808B2 (en) | 2014-05-02 | 2019-02-21 | Excelsior Medical Corporation | Strip package for antiseptic cap |
| CN107074863B (zh) | 2014-06-05 | 2019-12-03 | 沃泰克斯药物股份有限公司 | Atr激酶抑制剂的制备方法及其不同的固体形式 |
| PL3157566T3 (pl) * | 2014-06-17 | 2019-10-31 | Vertex Pharma | Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr |
| TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| WO2016061097A1 (en) * | 2014-10-13 | 2016-04-21 | Atrin Pharmaceuticals LLC | Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| DK3402532T3 (da) | 2016-01-11 | 2022-07-11 | Celator Pharmaceuticals Inc | Hæmning af ataxia telangiectasia og rad3-relateret protein (atr) |
| WO2018029117A1 (en) | 2016-08-10 | 2018-02-15 | Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) | New atr inhibitors for the use in cancer therapy |
| WO2018049400A1 (en) * | 2016-09-12 | 2018-03-15 | University Of Florida Research Foundation, Incorporated | Use of atr and chk1 inhibitor compounds |
| EP3515446B1 (en) | 2016-09-19 | 2023-12-20 | Novartis AG | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| JP2019529475A (ja) | 2016-09-27 | 2019-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法 |
| EP4194043A1 (en) | 2016-10-14 | 2023-06-14 | ICU Medical, Inc. | Sanitizing caps for medical connectors |
| EA039513B1 (ru) * | 2017-01-09 | 2022-02-04 | Селатор Фармасьютикалз, Инк. | Ингибитор атаксии-телеангиэкстазии и rad3-родственного белка (atr) и содержащие его липосомные композиции |
| TW201840319A (zh) | 2017-02-24 | 2018-11-16 | 德商拜耳廠股份有限公司 | Atr激酶抑制劑與鐳-223鹽之組合 |
| WO2018153972A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and antiandrogens |
| JOP20190197A1 (ar) | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر |
| US11439623B2 (en) | 2017-04-04 | 2022-09-13 | Case Western Reserve University | Method of modulating ribonucleotide reductase |
| WO2018199175A1 (ja) | 2017-04-27 | 2018-11-01 | 石原産業株式会社 | Ｎ－（４－ピリジル）ニコチンアミド化合物又はその塩 |
| US11266653B2 (en) | 2017-05-02 | 2022-03-08 | Novartis Ag | Combination therapy |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2019025440A1 (en) | 2017-08-04 | 2019-02-07 | Bayer Pharma Aktiengesellschaft | COMBINATION OF ATR KINASE INHIBITORS AND PD-1 / PD-L1 INHIBITORS |
| GB201715410D0 (en) | 2017-09-22 | 2017-11-08 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| CA3084863A1 (en) | 2017-12-08 | 2019-06-13 | Bayer Aktiengesellschaft | Predictive markers for atr kinase inhibitors |
| US11306079B2 (en) | 2017-12-21 | 2022-04-19 | Incyte Corporation | 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors |
| AU2018397736A1 (en) * | 2017-12-29 | 2020-07-09 | Vertex Pharmaceuticals Incorporated | Methods of cancer treatment using an ATR inhibitor |
| MD3762368T2 (ro) | 2018-03-08 | 2022-07-31 | Incyte Corp | Compuși diol aminopirazină ca inhibitori ai PI3K-Y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| ES3009674T3 (en) | 2018-09-26 | 2025-03-31 | Merck Patent Gmbh | Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer |
| CN113164447A (zh) | 2018-10-15 | 2021-07-23 | 默克专利股份公司 | 利用dna烷化剂和atr抑制剂的组合疗法 |
| EP3866805A1 (en) | 2018-10-16 | 2021-08-25 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
| JP2022510501A (ja) | 2018-10-30 | 2022-01-26 | リペア セラピューティクス インコーポレイテッド | 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法 |
| US11517732B2 (en) | 2018-11-07 | 2022-12-06 | Icu Medical, Inc. | Syringe with antimicrobial properties |
| ES3025633T3 (en) | 2019-05-13 | 2025-06-09 | Novartis Ag | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| WO2021050700A1 (en) * | 2019-09-13 | 2021-03-18 | The Broad Institute, Inc. | Cyclooxygenase-2 inhibitors and uses thereof |
| KR20220103987A (ko) | 2019-11-21 | 2022-07-25 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 피라졸로-헤테로아릴 유도체, 그것의 제조 방법, 및 그것의 의학적 용도 |
| CN115916966A (zh) * | 2020-01-30 | 2023-04-04 | 加利福尼亚大学董事会 | Strad结合剂及其用途 |
| WO2022063869A2 (en) * | 2020-09-24 | 2022-03-31 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
| IL302403A (en) | 2020-10-26 | 2023-06-01 | Merck Patent Gmbh | Atr inhibitors for use in the treatment of viral infections |
| CN117794924A (zh) * | 2021-08-13 | 2024-03-29 | 苏州爱科百发生物医药技术有限公司 | 用作atr激酶抑制剂的化合物 |
| CN115703768B (zh) * | 2021-08-13 | 2024-12-17 | 苏州爱科百发生物医药技术有限公司 | 用作atr激酶抑制剂的化合物 |
| CA3181279A1 (en) * | 2022-03-24 | 2023-09-24 | Bloom Energy Corporation | Fuel cell stack assembly including heat sink inserts |
| US20250352539A1 (en) | 2022-06-15 | 2025-11-20 | Astrazeneca Ab | Combination therapy for treating cancer |
| CN118255760A (zh) * | 2022-12-27 | 2024-06-28 | 江苏亚虹医药科技股份有限公司 | 一种嘧啶类化合物及其制备方法和医药用途 |
| PY2404641A (es) * | 2023-01-30 | 2024-10-03 | Eurofarma Laboratorios S A | COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y SUS KITS |
| CN116655619A (zh) * | 2023-06-05 | 2023-08-29 | 南京康立凯医药科技有限公司 | 一种2h-吲唑类化合物及其制备方法和应用 |
| CN117024413B (zh) * | 2023-10-07 | 2024-01-09 | 天津匠新致成科技有限公司 | 3-氨基吡嗪-2-甲酰胺类靶向蛋白水解嵌合体及其制备方法、药物组合物和应用 |
| WO2025181153A1 (en) | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with pi3k alpha inhibitors |
| WO2025201332A1 (zh) * | 2024-03-26 | 2025-10-02 | 勤浩医药（苏州）有限公司 | 噁二唑化合物、包含其的药物组合物及其用途 |
| WO2025229051A1 (en) | 2024-05-03 | 2025-11-06 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with antiandrogen agent |
| WO2025233224A1 (en) | 2024-05-09 | 2025-11-13 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with anti-pd(l)1 therapy |
| CN120097926B (zh) * | 2025-03-07 | 2026-01-30 | 杭州师范大学 | 一种选择性hpk1抑制剂及其制备方法和应用 |
Family Cites Families (226)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309430A (en) * | 1980-06-27 | 1982-01-05 | Merck & Co., Inc. | Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same |
| JPS62270623A (ja) | 1985-12-07 | 1987-11-25 | Daicel Chem Ind Ltd | ビス（４−アミノフエニル）ピラジンおよびその製法、ならびにポリイミドおよびその製法 |
| JPS63208520A (ja) | 1987-02-26 | 1988-08-30 | Terumo Corp | ピラジン誘導体を含有する血小板凝集抑制剤 |
| US5329012A (en) | 1987-10-29 | 1994-07-12 | The Research Foundation Of State University Of New York | Bis(acyloxmethyl)imidazole compounds |
| JPH0272370A (ja) | 1988-09-07 | 1990-03-12 | Konica Corp | 電子写真感光体 |
| JPH0272372A (ja) | 1988-09-07 | 1990-03-12 | Konica Corp | 電子写真感光体 |
| JPH0374370A (ja) | 1989-08-16 | 1991-03-28 | Terumo Corp | ピラジン誘導体およびこれを含有する血小板凝集抑制剤または抗炎症剤 |
| JP2597917B2 (ja) * | 1990-04-26 | 1997-04-09 | 富士写真フイルム株式会社 | 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料 |
| US5572248A (en) | 1994-09-19 | 1996-11-05 | Teleport Corporation | Teleconferencing method and system for providing face-to-face, non-animated teleconference environment |
| EP0914318A1 (en) | 1996-05-11 | 1999-05-12 | Kings College London | Pyrazines |
| JP4026876B2 (ja) | 1996-09-05 | 2007-12-26 | 日本食品化工株式会社 | 発光性シクロデキストリン誘導体及びその製造方法 |
| JP2002241379A (ja) | 1997-03-21 | 2002-08-28 | Dainippon Pharmaceut Co Ltd | ３−オキサジアゾリルキノキサリン誘導体 |
| WO1999044609A1 (en) | 1998-03-03 | 1999-09-10 | Merck & Co., Inc. | FUSED PIPERIDINE SUBSTITUTED ARYLSULFONAMIDES AS β3-AGONISTS |
| DE19826671A1 (de) | 1998-06-16 | 1999-12-23 | Hoechst Schering Agrevo Gmbh | 1,3-Oxazolin- und 1,3-Thiazolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
| CN1146561C (zh) | 1998-07-16 | 2004-04-21 | 盐野义制药株式会社 | 具有抗肿瘤活性的嘧啶衍生物 |
| US7023913B1 (en) | 2000-06-14 | 2006-04-04 | Monroe David A | Digital security multimedia sensor |
| ES2267492T3 (es) | 1999-02-05 | 2007-03-16 | Debiopharm S.A. | Derivados de ciclosporina y procedimiento de preparacion de dichos derivados. |
| US6738073B2 (en) | 1999-05-12 | 2004-05-18 | Imove, Inc. | Camera system with both a wide angle view and a high resolution view |
| EP1377554A1 (en) | 1999-06-16 | 2004-01-07 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
| US7015954B1 (en) | 1999-08-09 | 2006-03-21 | Fuji Xerox Co., Ltd. | Automatic video system using multiple cameras |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| PT1237880E (pt) | 1999-12-17 | 2008-03-05 | Novartis Vaccines & Diagnostic | Inibidores baseados em pirazina da cinase 3 da glicogénio sintase |
| AR029489A1 (es) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
| US6849660B1 (en) | 2000-08-01 | 2005-02-01 | Isis Pharmaceuticals, Inc. | Antimicrobial biaryl compounds |
| JP2002072370A (ja) | 2000-08-29 | 2002-03-12 | Fuji Photo Optical Co Ltd | ペーパーマガジン及び写真焼付装置 |
| JP2002072372A (ja) | 2000-09-04 | 2002-03-12 | Fuji Photo Film Co Ltd | 画像形成用シート体の切断装置 |
| US6829391B2 (en) | 2000-09-08 | 2004-12-07 | Siemens Corporate Research, Inc. | Adaptive resolution system and method for providing efficient low bit rate transmission of image data for distributed applications |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| ATE524441T1 (de) | 2000-12-28 | 2011-09-15 | Daiichi Seiyaku Co | Vla-4-inhibitoren |
| US8085293B2 (en) | 2001-03-14 | 2011-12-27 | Koninklijke Philips Electronics N.V. | Self adjusting stereo camera system |
| US6759657B2 (en) | 2001-03-27 | 2004-07-06 | Kabushiki Kaisha Toshiba | Infrared sensor |
| JPWO2002080899A1 (ja) | 2001-03-30 | 2005-01-06 | エーザイ株式会社 | 消化器疾患治療剤 |
| US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
| DE60229059D1 (de) * | 2001-05-08 | 2008-11-06 | Univ Yale | Proteomimetische verbindungen und verfahren |
| SE0102438D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| JP2003074370A (ja) | 2001-09-05 | 2003-03-12 | Suzuki Motor Corp | エンジンのベルト保護装置 |
| USRE40794E1 (en) | 2001-09-26 | 2009-06-23 | Merck & Co., Inc. | Crystalline forms of carbapenem antibiotics and methods of preparation |
| GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| US6992087B2 (en) * | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| WO2003045924A1 (en) | 2001-11-21 | 2003-06-05 | Pharmacia & Upjohn Company | Substituted aryl 1,4-pyrazine derivatives |
| US6693097B2 (en) | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| RU2004126671A (ru) * | 2002-02-06 | 2005-04-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероарилсоединения, полезные в качестве ингибиторов gsk-3 |
| ATE395343T1 (de) | 2002-03-13 | 2008-05-15 | Janssen Pharmaceutica Nv | Sulfonylderivate als histone-deacetylase- inhibitoren |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| US7043079B2 (en) | 2002-04-25 | 2006-05-09 | Microsoft Corporation | “Don't care” pixel interpolation |
| GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| US7704995B2 (en) * | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| CA2484209C (en) * | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| KR20050004214A (ko) | 2002-05-31 | 2005-01-12 | 에자이 가부시키가이샤 | 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물 |
| AU2003245669A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| US7015227B2 (en) | 2002-06-21 | 2006-03-21 | Cgi Pharmaceuticals, Inc. | Certain amino-substituted monocycles as kinase modulators |
| AU2003282679A1 (en) | 2002-10-04 | 2004-05-04 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
| US20040075741A1 (en) | 2002-10-17 | 2004-04-22 | Berkey Thomas F. | Multiple camera image multiplexer |
| US7385626B2 (en) | 2002-10-21 | 2008-06-10 | Sarnoff Corporation | Method and system for performing surveillance |
| US20040100560A1 (en) | 2002-11-22 | 2004-05-27 | Stavely Donald J. | Tracking digital zoom in a digital video camera |
| SE0203752D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| SE0203754D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| RS53118B (sr) | 2003-02-26 | 2014-06-30 | Sugen Inc. | Aminoheteroaril jedinjenja kao inhibitori protein kinaze |
| US7684624B2 (en) | 2003-03-03 | 2010-03-23 | Smart Technologies Ulc | System and method for capturing images of a target area on which information is recorded |
| MXPA05009245A (es) * | 2003-03-11 | 2005-10-19 | Pfizer Prod Inc | Nuevos compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf). |
| EP1606266A4 (en) * | 2003-03-21 | 2008-06-25 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| US20060293339A1 (en) | 2003-03-24 | 2006-12-28 | Chakravarty Prasun K | Biaryl substituted 6-membered heterocycles as sodium channel blockers |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| GB2400514B (en) | 2003-04-11 | 2006-07-26 | Hewlett Packard Development Co | Image capture method |
| CA2524867A1 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| WO2004103991A1 (en) | 2003-05-20 | 2004-12-02 | 'chemical Diversity Research Institute', Ltd. | 2-substituted piperidines, focused library and a pharmaceutical compound |
| US20050123902A1 (en) | 2003-05-21 | 2005-06-09 | President And Fellows Of Harvard College | Human papillomavirus inhibitors |
| PE20050206A1 (es) | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| US7986339B2 (en) | 2003-06-12 | 2011-07-26 | Redflex Traffic Systems Pty Ltd | Automated traffic violation monitoring and reporting system with combined video and still-image data |
| JP2005020227A (ja) | 2003-06-25 | 2005-01-20 | Pfu Ltd | 画像圧縮装置 |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| WO2005034952A2 (en) * | 2003-10-07 | 2005-04-21 | The Feinstein Institute For Medical Research | Isoxazole and isothiazole compounds useful in the treatment of inflammation |
| US20050116968A1 (en) | 2003-12-02 | 2005-06-02 | John Barrus | Multi-capability display |
| EP1694670A1 (en) | 2003-12-16 | 2006-08-30 | GPC Biotech AG | Pyrazine derivatives as effective compounds against infectious diseases |
| JP2007524682A (ja) | 2004-02-12 | 2007-08-30 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−５の調節物質としてのビピリジルアミド |
| US20050276765A1 (en) | 2004-06-10 | 2005-12-15 | Paul Nghiem | Preventing skin damage |
| JP2008502687A (ja) | 2004-06-14 | 2008-01-31 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| US7626021B2 (en) * | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| BRPI0513899A (pt) * | 2004-07-27 | 2008-05-20 | Sgx Pharmaceuticals Inc | moduladores de cinase heterocìclica de anel fundido |
| WO2006021886A1 (en) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
| GEP20104906B (en) | 2004-08-26 | 2010-02-25 | Pfizer | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
| US7730406B2 (en) | 2004-10-20 | 2010-06-01 | Hewlett-Packard Development Company, L.P. | Image processing system and method |
| US7705042B2 (en) | 2004-10-22 | 2010-04-27 | Janssen Pharmaceutica Nv | Class of arylamide compounds useful as inhibitors of c-fms kinase |
| WO2006053342A2 (en) | 2004-11-12 | 2006-05-18 | Osi Pharmaceuticals, Inc. | Integrin antagonists useful as anticancer agents |
| ZA200704888B (en) | 2004-11-22 | 2009-02-25 | Vertex Pharma | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
| JP4810669B2 (ja) | 2004-11-25 | 2011-11-09 | コニカミノルタホールディングス株式会社 | 有機エレクトロルミネッセンス素子、表示装置及び照明装置 |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| CA2590261C (en) | 2004-12-27 | 2011-08-16 | Alcon, Inc. | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions |
| GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| US7622583B2 (en) * | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| GB0501999D0 (en) * | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CN101163692B (zh) | 2005-02-16 | 2012-01-18 | 先灵公司 | 具有cxcr3拮抗活性的杂环取代的哌嗪 |
| AU2006239632B2 (en) | 2005-04-25 | 2012-03-15 | Merck Patent Gmbh | Novel AZA- heterocycles serving as kinase inhibitors |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| JP2008543754A (ja) | 2005-06-09 | 2008-12-04 | メルク エンド カムパニー インコーポレーテッド | チェックポイントキナーゼの阻害剤 |
| CA2617413A1 (en) | 2005-08-02 | 2007-02-08 | Lexicon Pharmaceuticals, Inc. | 2-aminoaryl pyridines as protein kinases inhibitors |
| WO2007015632A1 (en) * | 2005-08-04 | 2007-02-08 | Cgk Co., Ltd. | Atm and atr inhibitor |
| US7394926B2 (en) | 2005-09-30 | 2008-07-01 | Mitutoyo Corporation | Magnified machine vision user interface |
| US7806604B2 (en) | 2005-10-20 | 2010-10-05 | Honeywell International Inc. | Face detection and tracking in a wide field of view |
| TW200736260A (en) | 2005-11-10 | 2007-10-01 | Smithkline Beecham Corp | Inhibitors of Akt activity |
| DE602006011363D1 (de) | 2005-12-01 | 2010-02-04 | Hoffmann La Roche | Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer |
| EP1970377A4 (en) | 2005-12-09 | 2013-02-27 | Meiji Seika Kaisha | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THIS AS AN ACTIVE SUBSTANCE |
| BRPI0620668A2 (pt) | 2005-12-14 | 2011-11-22 | Du Pont | composto da fórmula 1, composição que compreende composto, composição de controle de pragas invertebradas, composição de pulverização, composição de isca, dispositivo de armadilha, métodos de controle de pragas invertebradas, método de controle de baratas, formigas ou cupins e método de proteção de sementes contra pragas invertebradas |
| JP2009521494A (ja) | 2005-12-22 | 2009-06-04 | アルコン リサーチ， リミテッド | ｒｈｏキナーゼ媒介性疾患および状態を治療するための（インダゾール−５−イル）−ピラジンおよび（１，３−ジヒドロインドール−２−オン）−ピラジン |
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| ITMI20060311A1 (it) | 2006-02-21 | 2007-08-22 | Btsr Int Spa | Dispositivo perfezionato di alimentazione di filo o filatio ad una macchina tessile e metodo per attuare tale alimentazione |
| GB0603684D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| WO2007096764A2 (en) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
| TW200800203A (en) | 2006-03-08 | 2008-01-01 | Astrazeneca Ab | New use |
| WO2007111904A2 (en) | 2006-03-22 | 2007-10-04 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors for the treatment of proliferative disorders |
| US7574131B2 (en) | 2006-03-29 | 2009-08-11 | Sunvision Scientific Inc. | Object detection system and method |
| MX2008012658A (es) | 2006-03-31 | 2008-12-16 | Schering Corp | Inhibidores de cinasa. |
| US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| CA2655857C (en) * | 2006-06-22 | 2014-12-02 | Mallinckrodt Inc. | Pyrazine derivatives with extended conjugation and uses thereof |
| US20080039450A1 (en) | 2006-06-22 | 2008-02-14 | Jensen Annika J | Compounds |
| EP1900727A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
| KR20090073121A (ko) | 2006-09-29 | 2009-07-02 | 노파르티스 아게 | Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘 |
| GB0619342D0 (en) | 2006-09-30 | 2006-11-08 | Vernalis R&D Ltd | New chemical compounds |
| RU2454405C2 (ru) | 2006-10-04 | 2012-06-27 | Ф.Хоффманн-Ля Рош Аг | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина |
| US7981893B2 (en) | 2006-10-19 | 2011-07-19 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| US8148361B2 (en) | 2006-11-10 | 2012-04-03 | Bristol-Myers Squibb Company | Kinase inhibitors |
| US20080132698A1 (en) | 2006-11-30 | 2008-06-05 | University Of Ottawa | Use of N-oxide compounds in coupling reactions |
| CL2007003627A1 (es) | 2006-12-15 | 2008-07-25 | Bayer Schering Pharma Ag | Compuestos derivados de 3-h-pirazolopiridinas; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades de crecimiento vascular desregulado tal como leucemia mielogena aguda, retinopatia, artritis reumatoide, psorias |
| WO2008079291A2 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| ES2431163T3 (es) | 2007-03-01 | 2013-11-25 | Novartis Ag | Inhibidores de PIM quinasa y métodos para su uso |
| JP2008260691A (ja) | 2007-04-10 | 2008-10-30 | Bayer Cropscience Ag | 殺虫性アリールイソオキサゾリン誘導体 |
| RU2009141185A (ru) | 2007-04-10 | 2011-05-20 | Байер КропСайенс АГ (DE) | Инсектицидные производные арилизоксазолина |
| PE20090288A1 (es) | 2007-05-10 | 2009-04-03 | Smithkline Beecham Corp | Derivados de quinoxalina como inhibidores de la pi3 quinasa |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| UY31137A1 (es) | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
| EP2012409A2 (en) | 2007-06-19 | 2009-01-07 | Hitachi, Ltd. | Rotating electrical machine |
| JP2009027904A (ja) | 2007-06-19 | 2009-02-05 | Hitachi Ltd | 回転電機 |
| WO2008156174A1 (ja) | 2007-06-21 | 2008-12-24 | Taisho Pharmaceutical Co., Ltd. | ピラジンアミド化合物 |
| US20090005381A1 (en) * | 2007-06-26 | 2009-01-01 | Philip Manton Brown | Methods of treating serotonin-mediated diseases and disorders |
| US8461189B2 (en) | 2007-06-27 | 2013-06-11 | Merck Sharp & Dohme Corp. | Pyridyl derivatives as histone deacetylase inhibitors |
| GB0713259D0 (en) | 2007-07-09 | 2007-08-15 | Astrazeneca Ab | Pyrazine derivatives 954 |
| WO2009014637A2 (en) | 2007-07-19 | 2009-01-29 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
| AU2008275891B2 (en) | 2007-07-19 | 2013-10-10 | H.Lundbeck A/S | 5-membered heterocyclic amides and related compounds |
| KR20100038119A (ko) | 2007-08-01 | 2010-04-12 | 화이자 인코포레이티드 | 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도 |
| WO2009024825A1 (en) | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
| WO2009037247A1 (en) | 2007-09-17 | 2009-03-26 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
| JP2011500778A (ja) | 2007-10-25 | 2011-01-06 | アストラゼネカ・アクチエボラーグ | ピリジン及びピラジン誘導体−０８３ |
| EP2265270A1 (en) | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
| ATE522536T1 (de) * | 2008-02-25 | 2011-09-15 | Hoffmann La Roche | Pyrrolopyrazin-kinasehemmer |
| KR101261514B1 (ko) * | 2008-02-25 | 2013-05-07 | 에프. 호프만-라 로슈 아게 | 피롤로피라진 키나아제 저해제 |
| EP2247593B1 (en) * | 2008-02-25 | 2011-08-10 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
| CA2716223A1 (en) * | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
| EP2265574A1 (en) | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| US8110576B2 (en) * | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
| GB0814364D0 (en) | 2008-08-05 | 2008-09-10 | Eisai London Res Lab Ltd | Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase |
| US8012976B2 (en) | 2008-08-06 | 2011-09-06 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
| JP5576370B2 (ja) | 2008-08-06 | 2014-08-20 | ファイザー・インク | Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物 |
| JP2010077286A (ja) | 2008-09-26 | 2010-04-08 | Aica Kogyo Co Ltd | シリコーン樹脂組成物および粘着フィルム |
| CN102317277A (zh) | 2008-10-21 | 2012-01-11 | 沃泰克斯药物股份有限公司 | C-met蛋白激酶抑制剂 |
| JP5702293B2 (ja) | 2008-11-10 | 2015-04-15 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| AU2009324894B2 (en) | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
| ES2464458T3 (es) | 2008-12-05 | 2014-06-02 | F. Hoffmann-La Roche Ag | Pirrolopirazinil-ureas como inhibidores de quinasas |
| BRPI0924084B1 (pt) | 2008-12-19 | 2021-12-21 | Vertex Pharmaceuticals Incorporated | Derivados de pirazina e composição farmacêutica que os compreende |
| US20110053923A1 (en) | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
| CA2748099C (en) | 2008-12-22 | 2017-02-28 | Array Biopharma Inc. | 7-phenoxychroman carboxylic acid derivatives |
| WO2010075376A2 (en) * | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
| TW201036946A (en) | 2009-01-30 | 2010-10-16 | Toyama Chemical Co Ltd | N-acylanthranilic acid derivative or salt thereof |
| JP5353279B2 (ja) | 2009-02-06 | 2013-11-27 | Ｊｎｃ株式会社 | セレンテラミド又はその類縁体の製造方法 |
| RU2011137419A (ru) * | 2009-02-11 | 2013-03-20 | Суновион Фармасьютикалз Инк. | Обратные агонисты и антагонисты гистамина н3 и способы их применения |
| CN101537007A (zh) | 2009-03-18 | 2009-09-23 | 中国医学科学院血液病医院（血液学研究所） | N-(噻吩-2)吡唑并[1,5-a]嘧啶-3-甲酰胺类化合物在制备抗恶性肿瘤药物方面的应用 |
| EP2411007A4 (en) * | 2009-03-27 | 2012-12-05 | Uab Research Foundation | MODULATION OF IRES-MEDIATED TRANSLATION |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| DK2454892T3 (en) | 2009-07-13 | 2015-04-20 | Widex As | HEARING-AID adapted to detect brain waves and a method for HOW TO ADAPT a hearing aid |
| EP2454262B1 (en) | 2009-07-15 | 2014-05-14 | Abbott Laboratories | Pyrrolopyrazine inhibitors of kinases |
| EP2461688B1 (en) | 2009-08-07 | 2016-03-16 | Dow AgroSciences LLC | Pesticidal compositions |
| JP2011042639A (ja) | 2009-08-24 | 2011-03-03 | Kowa Co | ビフェニルピラジン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤 |
| CN101671336B (zh) | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 |
| DE102009043260A1 (de) | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
| AU2010303567B2 (en) | 2009-10-06 | 2016-06-09 | Millennium Pharmaceuticals, Inc | Heterocyclic compounds useful as PDK1 inhibitors |
| EP2498778A1 (en) | 2009-11-13 | 2012-09-19 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer |
| PL2526090T3 (pl) | 2010-01-18 | 2016-04-29 | Medicines For Malaria Venture Mmv | Nowe środki przeciwmalaryczne |
| US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| WO2011124998A1 (en) | 2010-04-08 | 2011-10-13 | Pfizer Inc. | Substituted 3,5- di phenyl - isoxazoline derivatives as insecticides and acaricides |
| ES2602475T3 (es) | 2010-04-15 | 2017-02-21 | Tracon Pharmaceuticals, Inc. | Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER |
| US8916593B2 (en) | 2010-05-04 | 2014-12-23 | Pfizer Inc. | Alkoxy-substituted 2-aminopyridines as ALK inhibitors |
| JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| US8962631B2 (en) * | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US9062008B2 (en) * | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| AU2011253025A1 (en) | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2011143422A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
| EP2569287B1 (en) * | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| RU2012152354A (ru) | 2010-05-20 | 2014-06-27 | Ф. Хоффманн-Ля Рош Аг | Производные пирролопиразина в качестве ингибиторов syk и jak |
| BR112012029437A2 (pt) | 2010-05-20 | 2017-03-07 | F Hoffmann - La Roche Ag | derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk |
| WO2011163527A1 (en) * | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| CN102311396B (zh) * | 2010-07-05 | 2015-01-07 | 暨南大学 | 一种吡嗪类衍生物和其制备方法及在制药中的应用 |
| EP2407478A1 (en) | 2010-07-14 | 2012-01-18 | GENETADI Biotech, S.L. | New cyclotetrapeptides with pro-angiogenic properties |
| JP5782238B2 (ja) | 2010-07-30 | 2015-09-24 | ルネサスエレクトロニクス株式会社 | 電圧検出回路及びその制御方法 |
| AU2012225805B2 (en) | 2011-03-04 | 2017-03-02 | Lexicon Pharmaceuticals, Inc. | MST1 kinase inhibitors and methods of their use |
| US8962623B2 (en) | 2011-03-04 | 2015-02-24 | Locus Pharmaceuticals, Inc. | Aminopyrazine compounds |
| WO2012138938A1 (en) | 2011-04-05 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
| MX2013013331A (es) | 2011-05-17 | 2014-10-17 | Principia Biopharma Inc | Derivados de azaindol como inhibidores de tirosina-cinasas. |
| EP2723745A1 (en) * | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| JP2014517079A (ja) * | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| JP2014522818A (ja) * | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| WO2013049720A1 (en) * | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| IN2014CN02501A (enExample) | 2011-09-30 | 2015-06-26 | Vertex Pharma | |
| SG10201606774UA (en) * | 2011-09-30 | 2016-10-28 | Vertex Pharma | Processes for making compounds useful as inhibitors of atr kinase |
| WO2013049719A1 (en) * | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| MX2014003796A (es) | 2011-09-30 | 2015-01-16 | Vertex Pharma | Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
| EP2776429A1 (en) * | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013071093A1 (en) * | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| US8841449B2 (en) * | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| EP2776422A1 (en) * | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776421A1 (en) * | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US20140044802A1 (en) | 2012-04-05 | 2014-02-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| CN103373996A (zh) | 2012-04-20 | 2013-10-30 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的二并环衍生物 |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| SMT202000713T1 (it) | 2012-12-07 | 2021-03-15 | Vertex Pharma | Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro |
| JP6096005B2 (ja) | 2013-02-26 | 2017-03-15 | リンテック株式会社 | シート剥離装置および剥離方法 |
| HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| CN107074863B (zh) | 2014-06-05 | 2019-12-03 | 沃泰克斯药物股份有限公司 | Atr激酶抑制剂的制备方法及其不同的固体形式 |
| PL3157566T3 (pl) | 2014-06-17 | 2019-10-31 | Vertex Pharma | Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr |
-
2009
- 2009-12-18 BR BRPI0924084-5A patent/BRPI0924084B1/pt active IP Right Grant
- 2009-12-18 EP EP17205270.6A patent/EP3354650B1/en active Active
- 2009-12-18 JP JP2011542506A patent/JP5753093B2/ja active Active
- 2009-12-18 PT PT97989917T patent/PT2376485T/pt unknown
- 2009-12-18 SG SG10201607592PA patent/SG10201607592PA/en unknown
- 2009-12-18 KR KR1020177018220A patent/KR101958632B1/ko not_active Expired - Fee Related
- 2009-12-18 AU AU2009327357A patent/AU2009327357C1/en active Active
- 2009-12-18 EP EP22156312.5A patent/EP4059932A1/en not_active Withdrawn
- 2009-12-18 ES ES17205270T patent/ES2921576T3/es active Active
- 2009-12-18 CA CA2747252A patent/CA2747252C/en active Active
- 2009-12-18 CA CA3013000A patent/CA3013000C/en active Active
- 2009-12-18 HU HUE09798991A patent/HUE036068T2/hu unknown
- 2009-12-18 SM SM20180181T patent/SMT201800181T1/it unknown
- 2009-12-18 SI SI200931816T patent/SI2376485T1/en unknown
- 2009-12-18 NZ NZ593969A patent/NZ593969A/xx unknown
- 2009-12-18 HR HRP20180385TT patent/HRP20180385T1/hr unknown
- 2009-12-18 CN CN201610960222.7A patent/CN106496210B/zh active Active
- 2009-12-18 MX MX2011006503A patent/MX2011006503A/es active IP Right Grant
- 2009-12-18 PL PL17205270T patent/PL3354650T3/pl unknown
- 2009-12-18 RS RS20180262A patent/RS56995B1/sr unknown
- 2009-12-18 CN CN201610956094.9A patent/CN106496209B/zh active Active
- 2009-12-18 DK DK17205270.6T patent/DK3354650T3/da active
- 2009-12-18 CN CN200980155778.7A patent/CN102300862B/zh active Active
- 2009-12-18 PL PL09798991T patent/PL2376485T3/pl unknown
- 2009-12-18 RU RU2011129761/04A patent/RU2604066C2/ru active
- 2009-12-18 HR HRP20220581TT patent/HRP20220581T1/hr unknown
- 2009-12-18 KR KR1020147035688A patent/KR101755216B1/ko not_active Expired - Fee Related
- 2009-12-18 US US12/642,447 patent/US8841308B2/en active Active
- 2009-12-18 NO NO09798991A patent/NO2376485T3/no unknown
- 2009-12-18 EP EP09798991.7A patent/EP2376485B1/en active Active
- 2009-12-18 SG SG2011044724A patent/SG172248A1/en unknown
- 2009-12-18 CN CN201610960262.1A patent/CN106518856B/zh active Active
- 2009-12-18 LT LTEP09798991.7T patent/LT2376485T/lt unknown
- 2009-12-18 RU RU2016141566A patent/RU2016141566A/ru unknown
- 2009-12-18 WO PCT/US2009/068827 patent/WO2010071837A1/en not_active Ceased
- 2009-12-18 DK DK09798991.7T patent/DK2376485T3/en active
- 2009-12-18 ES ES09798991.7T patent/ES2663222T3/es active Active
- 2009-12-18 KR KR1020117016218A patent/KR101745331B1/ko active Active
- 2009-12-18 SI SI200932162T patent/SI3354650T1/sl unknown
- 2009-12-18 LT LTEP17205270.6T patent/LT3354650T/lt unknown
- 2009-12-18 PT PT172052706T patent/PT3354650T/pt unknown
- 2009-12-21 TW TW103134778A patent/TWI543979B/zh active
- 2009-12-21 TW TW105117426A patent/TWI643854B/zh active
- 2009-12-21 TW TW098143971A patent/TWI478918B/zh active
- 2009-12-21 AR ARP090105005A patent/AR074822A1/es active IP Right Grant
-
2011
- 2011-06-16 IL IL213613A patent/IL213613A/en active IP Right Grant
- 2011-06-17 ZA ZA2011/04498A patent/ZA201104498B/en unknown
-
2014
- 2014-03-24 US US14/223,109 patent/US9365557B2/en active Active
- 2014-08-25 US US14/467,175 patent/US9701674B2/en active Active
- 2014-08-26 JP JP2014171200A patent/JP5894643B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-06 IL IL236602A patent/IL236602B/en active IP Right Grant
- 2015-10-06 JP JP2015198400A patent/JP6212527B2/ja active Active
-
2016
- 2016-04-29 US US15/142,286 patent/US20160311809A1/en not_active Abandoned
- 2016-08-31 AU AU2016222396A patent/AU2016222396B2/en active Active
-
2017
- 2017-05-30 US US15/608,630 patent/US10961232B2/en active Active
- 2017-08-16 JP JP2017157105A patent/JP6577537B2/ja active Active
-
2018
- 2018-02-26 AU AU2018201363A patent/AU2018201363C1/en active Active
- 2018-03-02 CY CY20181100268T patent/CY1120002T1/el unknown
- 2018-04-30 US US15/967,110 patent/US10479784B2/en active Active
- 2018-06-19 IL IL260158A patent/IL260158B/en active IP Right Grant
-
2019
- 2019-07-12 JP JP2019130031A patent/JP2019194250A/ja not_active Withdrawn
-
2021
- 2021-02-25 US US17/184,813 patent/US20230030414A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2663222T3 (es) | Derivados de pirazina útiles como inhibidores de la quinasa ATR | |
| JP2013529643A5 (enExample) | ||
| DK2978752T3 (en) | 6- (5-HYDROXY-1H-PYRAZOL-1-YL) NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | |
| JP2013529199A5 (enExample) | ||
| CN114174292A (zh) | 作为atr激酶抑制剂的取代的2-吗啉代吡啶衍生物 | |
| JP2013526541A5 (enExample) | ||
| CN121358725A (zh) | 双环衍生物parp抑制剂及其用途 | |
| JP2013526540A5 (enExample) | ||
| RU2012153675A (ru) | Соединения, пригодные в качестве ингибиторов atr киназы | |
| CN113454080A (zh) | 化合物、药物组合物和制备化合物的方法以及其使用方法 | |
| JP2013526539A5 (enExample) | ||
| JP2013526538A5 (enExample) | ||
| WO2013175281A1 (en) | Use of substituted 2-phenyl-3h-quinazolin-4-ones and analogs for inhibiting bromodomain and extra terminal domain (bet) proteins | |
| RU2011123647A (ru) | Соединения, полезные в качестве ингибиторов atr киназы | |
| TW201004949A (en) | Chemical compounds | |
| JP2015502925A (ja) | Ａｔｒキナーゼの阻害剤として有用なピラジン化合物 | |
| WO2020042995A1 (zh) | 一种高活性sting蛋白激动剂化合物 | |
| JP7855570B2 (ja) | 三環式のヘテロ環 | |
| CN104177363A (zh) | 双环杂环胺类Hedgehog信号通路抑制剂 | |
| TW202311262A (zh) | Menin-mll交互作用之抑制劑 | |
| CN111295380B (zh) | 一种高活性csf1r抑制剂化合物 | |
| ES2338060T3 (es) | Componentes de tipo ariloxi y ariltoxia-cetofenona para el tratamiento del cancer. | |
| JP2016540773A (ja) | Ａｔｒキナーゼの阻害剤として有用な化合物 | |
| CN110759963A (zh) | 一种稠环类化合物及其制备方法和用途 | |
| CN112028891B (zh) | 腺苷受体拮抗剂 |